PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase 3 trial.
CONCLUSIONS: Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy. This study does not support a biological effect of metformin in endometrial cancer and casts doubt on its potential application in the primary and adjuvant treatment settings.
PMID: 30563932 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Kitson S, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton P, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ Tags: Clin Cancer Res Source Type: research
More News: Burns | Cancer | Cancer & Oncology | Cancer of the Uterus | Diabetes | Eating Disorders & Weight Management | Endocrinology | Endometrial Cancer | Fortamet | Hysterectomy | Insulin | Metformin | Obesity | Study | Weight Loss | Women